Anti-inflammatory properties of IL-1 in carrageenan-induced paw oedema.
To evaluate any inhibitory effect of a single dose of human recombinant interleukin-1 beta (hrIL-1 beta) on the severity of carrageenan-induced oedema in rats (a commonly used model of acute inflammation), we first injected 0.1 ml of carrageenan (0.2%, 0.5%, or 2%) to induce mild, moderate, or severe inflammation, respectively into the right rear footpad. Then we promptly injected the interleukin (0.02, 0.2, or 2 micrograms) subcutaneously into the flank. The initial rapid increase in volume of the injected paw (within 2 h of the subplantar injection) was independent of the dose of carrageenan, whereas the increase in volume by 6 to 10 h was dose-dependent. All doses of HrIL-1 beta inhibited the carrageenan-induced swelling at the 6th hour. In the moderate and severe carrageenan-induced oedemas, the higher dose of HrIL-1 beta induced a delayed inflammation peaking at 10 h instead at 6 h.
Drelon
E
E
Laboratoire de Pharmacologie, URA CNRS 1288, Faculté de Médecine de Nancy, Vandeuvre les Nancy, France.
Gillet
P
P
Muller
N
N
Terlain
B
B
Netter
P
P
D000818:Animals; D002351:Carrageenan / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D007375:Interleukin-1; D011994:Recombinant Proteins; D002351:Carrageenan